The Beginning of Repeated Hemodialysis Treatment Enhances Some Platelet Functions in Uremic Patients
Author(s) -
Wojciech Krawczyk,
Anna Dmoszyńska,
Krzysztof Marczewski
Publication year - 1995
Publication title -
the nephron journals/nephron journals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.951
H-Index - 72
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000188747
Subject(s) - citation , medicine , icon , download , world wide web , library science , computer science , programming language
Wojciech Krawczyk, MD, Department of Internal Medicine and Dialysis Unit, Regional Hospital, ul. Szpitalna 53, 22-100 Chełm (Poland) Dear Sir, The thrombotic complications have become the predominant causes of mortality in uremic patients. An essential role in patho-genesis of these complications is played by platelet dysfunction. However, the disturbances of platelet function in uremic patients vary in dialyzed and nondialyzed patients. There is considerable disagreement as to what extent dialysis can reverse these abnormalities. Most investigations on this topic concerned the comparison between these two groups of patients simultaneously, but the patients in the groups were different [1-3]. We studied 10 uremic patients twice: first, in the period of conservative treatment (very-low-protein, low-phosphorus diet) and later on maintenance hemodialysis treatment (thrice weekly hemodialysis program, each for 4 h). We examined 8 males and 2 females, (aged 21-57 years, mean ± SD: 36.6 ± 17.1). Ten healthy blood donors, matched for age and sex were studied as controls. Medication known to affect platelet function as well as erythropoietin was excluded. Blood samples were collected by venipuncture in hemodialysis patients before the dialysis procedure. We studied the platelet count according to the Miesher and Ge-rarde method [4], bleeding time with the method of Mielke et al. [5], platelet aggregation according to Breddin [6] and, in addition, with the method of Born [7], using ADP as aggregating agent, platelet factor 3 (PF3) availability according to Saleem et al. [8] and platelet factor 4 (PF4) activity according to the method of O’Brien et al. [9]. Statistical analysis was performed using the Student t test. Table 1. Selected parameters of platelet hemostasis in uremic patients treated conservatively, in the same patients after 3 months of repeated hemodialysis treatment, and in control group (means ± standard deviations)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom